For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 20% to 21%. Revenue growth ranges by product line are: Total Omnipod of 21% to 22%; U.S. Omnipod of 19% to 21%; International Omnipod of 25% to 27%; Drug Delivery of (10)% to (5)%
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: